Myfxtools
  • Login
  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios
No Result
View All Result
  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios
  • Login
Myfxtools
Home News

NeuroPace Reports Strong Q2 Results and Raises 2023 Outlook

by Myfxtools
August 11, 2023
in News
Share on TwitterShare on Facebook

NeuroPace, a commercial-stage medical device company, experienced a surge in its stock price, with shares advancing by 13% to $4.65 following the release of its second-quarter earnings report. The company’s stock has more than tripled in value since the beginning of the year, indicating a strong performance.

In terms of financials, NeuroPace narrowed its loss for the three-month period ended June 30. It reported a loss of $9.1 million, or 36 cents per share, compared to a loss of $12.7 million, or 52 cents per share, during the same period last year. The results exceeded analysts’ expectations, with FactSet predicting a loss of 46 cents per share. Moreover, NeuroPace’s revenue showed significant growth, increasing from $10.2 million to $16.5 million. This positive result also surpassed analysts’ estimates of $12.6 million.

The rise in revenue can be attributed to increased utilization of the company’s RNS System by physicians and higher than expected revenue from DIXI Medical products. NeuroPace was also able to extend its cash runway by reducing its cash burn from $9.8 million to $4 million in the first quarter.

Building on these positive developments, NeuroPace revised its 2023 revenue outlook to a range of $59 million to $61 million, up from the previous projection of $52 million to $54 million.

Overall, NeuroPace’s second-quarter results and improved outlook for 2023 reflect the company’s strong performance and continued growth in the medical device market.

forex ea chart
Would you like to try out trading with an Expert Advisor?
Check Out Best Forex EAs Here
Tags: 2023 outlookmedical device companyNeuroPaceQ2 earningsstock market
Previous Post

Wynn Resorts Reports Profit in Q2 as Revenue Rises

Next Post

Novo Nordisk Raises Full-Year Guidance on Strong Demand for Ozempic and Wegovy

Next Post

Novo Nordisk Raises Full-Year Guidance on Strong Demand for Ozempic and Wegovy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

40 − 30 =

Recent Posts

  • Economic Calendar for the Week of June 29th
  • NZD/USD Strengthens as Fed Independence Questioned
  • USD/CNH Seen Ranging Narrowly With Downside Bias Building
  • Euro Climbs as Trump Fed Remarks Boost Rate-Cut Bets
  • Euro Poised for Higher Range on Strong Momentum
  • About Us
  • Contact Us
  • Privacy Policy
  • Risk Disclosure
Myfxtools turns raw trade logs into verified dashboards and AI-driven insights - helping traders see, share, and sharpen their edge.

© 2025, Myfxtools. All rights reserved.

AI Strategy Insight is educational and not financial advice.

  • Expert Advisors
  • Forex Signals
    • Best Forex Signals
  • Forex Brokers
  • Forex Trading
    • Forex Guides
    • Analytical Tools
    • Charting Software
  • Crypto Trading
  • Portfolios

© 2025, Myfxtools. All rights reserved.

AI Strategy Insight is educational and not financial advice.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In